Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.53 |
| ▸ | ACLY | P53396 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TTK | P33981 | 2/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.37 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.37 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.37 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15507926 | 1.00 | LRRK2 (0.53) | LRRK2ACLYALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL15507797 | 0.82 | LRRK2 (0.50) | LRRK2TTKHTTGAKSMN1; SMN2 | |
| SCHEMBL17056047 | 0.81 | TTK (0.45) | LRRK2ALDH1A1KMT2ATTKHTT | |
| SCHEMBL15507920 | 0.80 | TTK (0.45) | LRRK2ALDH1A1TTKHTTGAK | |
| SCHEMBL17049267 | 0.80 | LRRK2 (0.53) | LRRK2ACLYALDH1A1TTKTACR1 | |
| SCHEMBL30132235 | 0.80 | TTK (0.45) | LRRK2ALDH1A1TTKHTTGAK | |
| SCHEMBL5193649 | 0.77 | ALDH1A1 (0.53) | LRRK2ACLYALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL17055911 | 0.77 | LRRK2 (0.53) | LRRK2ALDH1A1KMT2ATTKHTT | |
| SCHEMBL17056056 | 0.77 | TTK (0.47) | LRRK2ALDH1A1KMT2ATTKHTT | |
| SCHEMBL15507908 | 0.76 | LRRK2 (0.52) | LRRK2TTKHTTGAKPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897877-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-02-13 | — | — | US | disclosed |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402912-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | LRRK2 513/4885ACLY 1420/4885ALDH1A1 3742/4885 |
| US-11897877-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | LRRK2 513/4885ACLY 1420/4885ALDH1A1 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.